{'fraction_non_alphanumeric': 0.02621359223300971, 'fraction_numerical': 0.0, 'mean_word_length': 6.01360544217687, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pre‐implantation genetic testing for aneuploidy: the past, present and future

Embryonic aneuploidy is often found in women undergoing assisted reproduction and is a common cause of poor outcomes, particularly in women of advanced maternal age and those with recurrent miscarriage and repetitive implantation failure. The aim of pre‐implantation genetic testing for aneuploidy (PGT‐A) is to select the most competent embryo for transfer, thus improving reproductive outcome. Initial PGT‐A techniques failed to show an improvement in delivery rates and, in some trials, demonstrated inferior outcomes; however, advances in technology, combined with robust culture media and vitrification techniques, have significantly improved outcomes. Recent debate has argued for the increased clinical application of PGT‐A, particularly in women of advanced maternal age; we provide an overview of PGT‐A, including its past and associated limitations, the evolution in technology and latest outcomes, and address potential future implications.